We have two more weeks left in June, and for the second quarter to end. The iShares Nasdaq Biotechnology ETF (IBB), a bellwether of investor sentiment, has lost nearly 8.5 percent of its value so far this quarter.
Provention Bio (PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, which has returned over 390% so far this quarter, leads the list of gainers in the second quarter, thanks to encouraging news about its type 1 diabetes candidate PRV-031.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.